Combined advances in haematopoietic cell transplantation (HCT) and intensive care
management have improved the survival of patients with haematological malignancies …

Patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) following
allogeneic hematopoietic stem cell transplantation (alloHSCT) have a poor prognosis, and …

Relapsed acute myeloid leukemia (AML) after an allogeneic hematopoietic cell transplant
(allo-HCT) entails a poor prognosis. Treating these cases is challenging due to lack of …

Allogeneic hematopoietic cell transplantation (HCT) is the treatment of choice for high-risk
myeloid and lymphoid leukemias. Relapse after allogeneic HCT is associated with a dismal …

The prognosis of patients with acute leukemia relapsed after allogeneic hematopoietic stem
cell transplantation (HSCT) is dismal. We aimed to evaluate the outcomes and prognostic …

The outcomes of patients with acute lymphoblastic leukaemia (ALL) presenting relapse after
allogeneic stem cell transplant (allo‐SCT) are poor, with few data available in this setting …

Background Allogeneic hematopoietic cell transplantation (HCT) is potentially curative for
hematological disease however can be complicated by relapse or graft failure (GF), for …

Allogeneic hematopoietic cell transplantation (HCT) can lead to considerable complications
and treatment-related mortality (TRM); therefore, a detailed assessment of risks is essential …

Abstract The EBMT Chronic Malignancies Working Party performed a retrospective analysis
of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017 …

Severe aplastic anemia (SAA) is a life-threatening hematological disorder. The major
therapies include matched sibling donor (MSD)-hematopoietic stem cell transplantation …